The Boy Scouts Dive in to a Different Dimension With The L. Ron Hubbard East Coast Theatre

L. Ron Hubbard East Coast Theatre actors perform a final rehearsal of the classic Science Fiction story “The Dangerous Dimension” at the Clearwater Community Volunteers Center in downtown Clearwater. In the audience were the Boy Scouts of Troop 313

L. Ron Hubbard's East Coast Golden Age Theatre opens rehearsal to the public for the first time at the Clearwater Community Volunteers Center in downtown

CLEARWATER, FLORIDA, USA, August 16, 2018 /EINPresswire.com/ — On Tuesday August 14, the Clearwater Community Volunteers Center, opened and supported by the Church of Scientology Flag Service Organization, hosted the L. Ron Hubbard East Coast Theatre in their final rehearsals of their upcoming presentation of L. Ron Hubbard’s pulp fiction story The Dangerous Dimension. The rehearsal served as an exclusive behind the scenes preview for Boy Scout Troop 313 before the Theater’s live performance on August 18 in the Scientology Information Center, located on the corner of Cleveland Street and Fort Harrison Ave.

This is the first time the Theatre allowed a group to see their rehearsal. The Boy Scouts saw how the theater polishes each final performance using costumes and sound effects.

“These actors practice every week to create a stellar performance that will bring people in the community together,” said Michael Soltero, Manager of the Center. “By opening their rehearsals to the Boy Scouts they accomplish what the Center was established for: bringing different community groups together. They’re doing as humanitarian L. Ron Hubbard wrote, ‘A community that pulls together can make a better society for all.”

The Dangerous Dimension by L. Ron Hubbard is based on Dr. Henry Mudge, who discovers the mathematical formula “Equation C”, which outlines a negative dimension. Using this equation, Dr. Mudge is instantly transported to any location in the solar system by simply thinking of it.

For more information about the Clearwater Community Volunteers Center or to attend an upcoming event, please call Michael Soltero at (727) 316-5309 or email ccvcenter@ccvfl.org.

About the Clearwater Community Volunteers:

The Clearwater Community Volunteers (CCV) have over 25 years of community service under their belt with over 150,000 families and children helped since their founding in 1992. CCV stays true to their reputation of helping others with their new center, located on the corner of Fort Harrison Ave. and Drew St. in downtown Clearwater, which facilitates the growth of non-profits by serving as a free event venue & meeting space. CCV and the CCV Center are sponsored by the Church of Scientology Flag Service Organization.

Pat Harney
Church of Scientology Flag Service Organization
727-467-6860
email us here


Source: EIN Presswire

Global Pharmacy Benefit Management Market (PBM) 2018 Analysis and Forecast to 2023 Research Report

MarketResearchNest.com adds “Global Pharmacy Benefit Management (PBM) Market 2018 by Manufacturers Regions Type and Application to 2023” report to its database.

PUNE, INDIA, August 16, 2018 /EINPresswire.com/ — MarketResearchNest.com adds “Global Pharmacy Benefit Management (PBM) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023” new reports to its research database. The report spread across 133 pages with tables and figures in it.

Pharmacy benefit manager (PBM) is a third-party administrator (TPA) of prescription drug programs for commercial health plans, self-insured employer plans, Medicare Part D plans, the Federal Employees Health Benefits Program, and state government employee plans.

This report focuses on the Pharmacy Benefit Management (PBM) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for Pharmacy Benefit Management (PBM) is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Order a purchase report copy of at https://www.marketresearchnest.com/report/purchase/403080 .

Market Segment by Manufacturers, this report covers
CVS Health (CVS)
Express Scripts
OptumRx (UnitedHealth)
Humana Pharmacy Solutions
Prime Therapeutics
Medimpact Healthcare
Magellan Health
BC/BS
Vidalink
Sea Rainbow
Cachet

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Inquire before Buying at https://www.marketresearchnest.com/report/enquirybuy/403080 .

Market Segment by Type, covers
commercial health plans
self-insured employer plans
Medicare Part D plans
Federal Employees Health Benefits Program
state government employee plans

Market Segment by Applications, can be divided into
Mail-order Pharmacy Services
Non-mail Pharmacy Services

There are 15 Chapters to deeply display the global Pharmacy Benefit Management (PBM) market.
Chapter 1, to describe Pharmacy Benefit Management (PBM) Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Pharmacy Benefit Management (PBM), with sales, revenue, and price of Pharmacy Benefit Management (PBM), in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Pharmacy Benefit Management (PBM), for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Pharmacy Benefit Management (PBM) market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Pharmacy Benefit Management (PBM) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Get a Report Details at https://www.marketresearchnest.com/Global-Pharmacy-Benefit-Management-PBM-Market-2018-by-Manufacturers-Regions-Type-and-Application-Forecast-to-2023.html .

About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

Contact Us
Mr. Jeet Jain
Sales Manager
sales@marketresearchnest.com
+1-240-284-8070 / +44-20-3290-4151

Mr Jeet
Market Research Nest
1-240-284-8070
email us here


Source: EIN Presswire

PetVivo Holdings, Inc. Moves Manufacturing Facility, Creates Research and Development Laboratory.

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

MINNEPOLIS, MINNESOTA, USA, August 16, 2018 /EINPresswire.com/ — PETVIVO HOLDINGS, INC. MOVES AND EXPANDS MANUFACTURING FACILITY. CREATES RESEARCH AND DEVELOPMENT LAB

(OTCMARKETS: PETV), PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company, is pleased to announce the moving of its manufacturing facility and the creation of a research and development lab.

In an effort to expand manufacturing and create a research and development facility, Petvivo, Inc. moved from Elite Solutions in Rochester, Minnesota to the home of CytoMedical Design Group LLC (cmdg) in St. Paul, Minnesota. The location has far better access for Petvivo employees and eliminates the costs of hotels and mileage which the company has been absorbing sending and supporting staff from Minneapolis for weeks at a time to work in Rochester.

“We estimate that our cost of manufacturing will be reduced substantially. It is also time to address our plan to continue improving our product and initiate our research and development plans. Assistance for both manufacturing and research will be available from staff members of the cmdg group. Cmdg has additional clean rooms and square footage for our use “commented Wes Hayne, CEO of Petvivo Holdings, Inc.

The move was performed in one week, coordinated with three different moving companies. Each company specializing in specific equipment, with different degrees of sensitivity. The move is now complete, and production is expected to resume within the next three weeks. The new surroundings and extra space will help in building the efficiencies of the manufacturing process.

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

Wes Hayne
Petvivo Holdings Inc
962-405-6216
email us here


Source: EIN Presswire

The Astronot makes its Canadian Premiere at the Regina International Film Festival in Saskatchewan

Pennan Brae wote, scored, starred in and co-produced The Astronot.

Regina International Film Festival

The Astronot is a feature film drama set during the 1960’s space race, written, scored, starring and co-produced by Pennan Brae.

It's an honour to have The Astronot make its Canadian premiere at the RIFF. As a Canadian, it's great to take part in a domestic festival and what better place than the lovely city of Regina?”

— Pennan Brae

REGINA, SASKATCHEWAN, CANADA, August 15, 2018 /EINPresswire.com/ — The Astronot, currently on the film festival circuit, is excited to announce its official Canadian premiere at the Regina International Film Festival in Regina, Saskatchewan. The feature film is an Official Selection in the Feature Film category and will screen at the Cineplex Odeon South on Thursday, August 16 at 11:00 am – 12:15 pm. (The Regina International Film Festival runs from August 14 – 18th.) The film has already won dozens of awards worldwide.

The feature film is a drama set during the space race of the 1960’s, written, scored, starring and co-produced by Pennan Brae. 

The film follows Daniel McKovsky, a young man who lost both his parents at a young age and whose only solace is in his fascination with space travel and the cosmos beyond. One day at the age of 30, he meets outgoing postal worker, Sandy Allister. This new inclusion into his otherwise lonely existence forces Daniel to confront his darkest fears of loss and emptiness which shall lead him towards becoming, The Astronot.

The Astronot was filmed in rural Oregon, using local cast and crew, including director Tim Cash of Far From Earth Films. The Astronot has already won accolades at various international film festivals in the USA, UK & Europe including Best Actor (Pennan Brae), Score (Pennan Brae) and Trailer.



'It's an honour to have The Astronot make its Canadian premiere at the RIFF. As a Canadian, it's great to take part in a domestic film festival and what better place than the lovely capital city of Regina.”- Pennan Brae



Also a musician, Pennan Brae’s upcoming album (also called, The Astronot), features 11 songs which serve as the film’s soundtrack. The first single, “Walk With Me” was already released to radio in the UK, Canada & Europe and received airplay on over 200 stations. The album was recorded at Blue Light Studio in Vancouver with producer Kaj Falch-Nielsen, with additional sessions taking place in Los Angeles with composer/producer Eric Alexandrakis, renowned drummer Steve Ferrone and INXS bassist Garry Gary Beers. The second single, ‘Crashland’ is set for release to Canadian radio one week following the Regina festival.


To view the trailer, please visit: www.TheAstronot.com.

Amanda Alexandrakis
Film Marketeers
970.377.0313
email us here

The Astronot Official Trailer


Source: EIN Presswire

Hardman Batchelor Places Jim Ramsey as Vice President, Americas Sales For National Instruments Corporation

Picture of Jim Ramsey

Jim Ramsey

Logo for Hardman Batchelor International

Hardman Batchelor International, a global retained executive search firm, completes Vice President Americas Sales search for National Instruments Corporation.

Jim Ramsey was a clear choice among a list of top national candidates given his relevant experience and admired reputation as a strong sales leader, mentor and coach.”

— Edward Batchelor, Managing Partner

AUSTIN, TEXAS, USA, August 15, 2018 /EINPresswire.com/ — Following a national search, global retained search firm Hardman Batchelor International has placed executive Jim Ramsey as the new Vice President, Americas Sales of National Instruments Corporation (NASDAQ: NADI) effective immediately. Headquartered in Austin, National Instruments develops and manufactures software and hardware products that engineers and scientists use for test, control and embedded design applications. In 2017, the company sold products to more than 35,000 companies with revenues of more than $1.29 billion and global operations across 50 countries. The search was led by Managing Partner, Edward Batchelor, software & technology practice leader of HBI.

Jim Ramsey brings over 30 years’ experience in sales and sales strategy, joining NI two and a half years ago to spearhead the Americas Partner strategy and team. Prior to NI, Jim spent most of his career at Maxim Integrated where he drove design influence across a $1 billion business achieving double-digit growth. In this Vice President of Sales for the Americas, he will have overall responsibility for the development and execution of the sales plan (representing 40% of the revenue of NI) with responsibility to increase the Company’s market share as well as capture new customers. He will also have dotted line responsibility for the regional marketing and operations functions partnered with the Americas region which are now centralized globally.

“Jim Ramsey was a clear choice among a list of top national candidates given his relevant experience and admired reputation as a strong sales leader, mentor and coach.” Mr. Batchelor said.

Hardman Batchelor also recently placed Paul Horton as Vice President, Global Operations at National Instruments Corporation. He brought a wealth of experience in Global Finance, Information Solutions and Sales Operations across General Motors, EDS, Hewlett Packard Enterprises Services and DXC Technology (CSC and HP Enterprises Merger). He most recently served as the Vice President of Global Sales Operations at DXC where he led project teams that designed the new company’s sales organization, processes and compensation.

About Hardman Batchelor International

Founded by former “Big Five Firm” Partner Edward Batchelor, Hardman Batchelor International is a groundbreaking global firm specializing in recruiting and assessing world-class Board Directors, CEOs and C-Level executives with a particular focus on confidential mandates and cultivating the underserved “Middle America” marketplace. The firm offers retained executive and board level search; reference checking; candidate benchmarking; and management assessment. It has been recognized as a 2018 Hunt Scanlon Global Talent Leader signifying quality, exceptional service and distinguished leadership in executive recruiting.

Edward Batchelor
Hardman Batchelor International
+1 512 761 3268
email us here


Source: EIN Presswire

Cutting-edge Research to be Presented at The Pacific Mesothelioma Center's Symposium on Mesothelioma at UCLA

On September 29th global experts will convene at The Luskin Conference Center at UCLA for the 8th International Symposium on Malignant Pleural Mesothelioma.

LOS ANGELES, CA, USA, August 15, 2018 /EINPresswire.com/ — On September 29th global experts on malignant pleural mesothelioma will again convene at the Meyer & Renee Luskin Conference Center at UCLA for the 8th Annual International Symposium on Malignant Pleural Mesothelioma (MPM), a rare form of cancer that results from exposure to asbestos and commonly affects the lining of the chest– the pleura. The event is jointly hosted by UCLA and the Pacific Mesothelioma Center (PMC).

The Symposium is geared towards physicians and offers continuing medical education (CME) credit. It will also provide up-to-date information on mesothelioma for medical students, nurses and other healthcare professionals, as well as mesothelioma patients, their families, and other interested parties. Topics will cover: Perioperative Immunotherapy; Mesothelioma Clinical Trials; Novel MRI Assessment of Mesothelioma Tumor Volume; Toxicities and Outcomes Using Whole Pleural Intensity – Modulated Proton Therapy; Understanding the Immune Response to Radiotherapy in a Dual Tumor Model of Mesothelioma; Integrative Molecular Characterization of Mesothelioma: Cancer Genome Atlas Project; A Modified Measles Virus Against Mesothelioma; An Exhaled Breath Biopsy Earmarks Exclusive Screening for MPM; Mesothelioma Immunotherapy by Controlling T Cell-Mediated Immunity; Overcoming the Immunosuppressive Tumor Microenvironment of Murine Malignant Mesothelioma and more.

The Symposium will be led by Robert B. Cameron, MD, FACS, Director of the UCLA Mesothelioma Comprehensive Research Program and Professor of Thoracic Surgery at the David Geffen School of Medicine at UCLA. The roster of distinguished international faculty at the Symposium will include Kevin G. Blyth, MD, MBchB, FRCP, University of Glasgow; Nicolas Boisgerault, PhD, CRCINA Cancer Research Center, France; Lisa M. Coussens, PhD, Oregon Health and Science University, Portland; Mikihiro Kohno, MD, PhD, University of Toronto, Canada; Marc Ladanyi, MD, Memorial Sloan Kettering, New York; Kevin Lamote, PhD, University of Antwerp, Belgium; Charles B. Simone II, MD, University of Maryland Medical Center, Baltimore, Maryland; Wesley Wilson, PhD Candidate, University of Western Australia Perth, Australia, as well as local experts from UCLA.

"There is so much exciting science from around the world in terms of treatment for mesothelioma, with promising medical advances and new research” said Dr. Cameron. “This year we have changed the format to concentrate more on clinical and research sessions and have incredible speakers from all around the world”. The symposium gives an unrivaled opportunity for both the medically savvy and general public, including mesothelioma patients, to not only learn first-hand about groundbreaking discoveries but also to exchange ideas.

Early Bird tickets can be purchased before September 6th online at http://www.cme.ucla.edu/courses/.

The Pacific Heart, Lung & Blood Institute (PHLBI) is a 501(c)(3) non-profit medical research institute established in 2002. One of the divisions, The Pacific Mesothelioma Center (PMC) is focused on the treatment and prevention of malignant pleural mesothelioma (MPM). The exploration of innovative ideas forms the foundation of PMC’s unique research program and provides the promise of future treatment breakthroughs. PMC is dedicated to educating the public on asbestos-related diseases and informing them of their best treatment options. PMC also connects newly diagnosed patients with other patients that have been through treatment and provides assistance and emotional support.

Clare Cameron
The Pacific Mesothelioma Center
310-478-4678
email us here


Source: EIN Presswire

Marrone Bio Innovations Submits Novel Bioherbicide to the EPA for Regulatory Approval

Novel mode of action for resistant weeds such as palmer amaranth

Marrone Bio Innovations (NASDAQ:MBII)

We are excited about what we have seen so far in 014 development. We have more work to determine appropriate doses on key target weeds, water volume, adjuvans and further expansion of the spectrum.”

— Amit Vasavada, Senior Vice President of R&D and Chief Technology Officer

DAVIS, CA, USA, August 14, 2018 /EINPresswire.com/ — Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, has submitted the registration package for its new bioherbicide, MBI-014, to the United States Environmental Protection Agency (EPA).

Weeds are a major source of yield losses for most cropping systems. According to various market research reports, herbicides account for 40% of the $50 billion global pesticide market. Of the approximately $7.2 billion chemical pesticides sold in the U.S. each year, nearly $4 billion are chemical herbicides.

Grower surveys repeatedly show that weed control is the number one cost of organic food production since chemical herbicides are not allowed. In organic growing systems, herbicide options are extremely limited, consisting almost entirely of non-selective soaps and acids that typically require repeat applications, lack residual activity, only affect plant areas into which they come in direct contact, and sometimes cost more than hand weeding. According to the Organic Trade Association, organic food sales reached $45 billion in the U.S. and is the fastest growing segment of food, growing an average of 9.1% annually since 2008.

MBI-014 is a water dispersible microbial herbicide made from a new species of heat-killed bacteria, Burkholderia rinojensis (strain A396). This new herbicide has a novel mode of action per research conducted at the USDA Agricultural Research Service. While additional development work and field trials need to be conducted, MBI-014 could prove to be a valuable new tool for weed control when used in conjunction with other herbicides in a grower’s integrated pest management (IPM) program.

MBI-014 demonstrates post-emergent herbicidal activity across a range of weeds in laboratory and field tests. It shows evidence of uptake and moderate movement through different plant tissues. MBI-014 is most effective on some of the most serious weeds, some of which have developed resistance to multiple herbicide classes, such as palmer amaranth, waterhemp and others in the pigweed family (Amaranthacae).

“We are excited about what we have seen so far in the development of MBI-014,” said Amit Vasavada, Senior Vice President of R&D and Chief Technology Officer at Marrone Bio Innovations. “We do have more work to do in order to determine such things as appropriate doses on key target weeds, water volume required, adjuvant package needed and further expansion of the spectrum of targeted weeds.”

Sources of cited information: Phillips McDougall Agribusiness Intelligence, Weed Science Society of America, University of Missouri, Organic Trade Association, Organic Farming Research Foundation, USDA.

Pam Marrone
Marrone Bio Innovations
5307502800
email us here


Source: EIN Presswire

SMi’s Exclusive Interview with Abon Pharmaceuticals, Director just released

Dr. Yanming Zu, Director at Abon Pharmaceuticals

Interview with Dr. Yanming Zu, Director

An exclusive interview with Dr. Yanming Zu, Director at Abon Pharmaceuticals has been released

NEW JERSEY , ISELIN, USA, August 14, 2018 /EINPresswire.com/ — SMi Reports: An exclusive interview with Dr. Yanming Zu, Director at Abon Pharmaceuticals, who will be presenting an Opening Address on 'Challenges of lyophilized product development’, in the run-up to the 4th annual Lyophilization USA Conference taking place 15th-16th November 2018, Iselin, New Jersey, USA. The two-day conference promises to provide a stimulating environment for delegates, with an impressive list of international industry experts from Pfizer, Amgen and Merck sharing their experience and thought-leadership across a full conference programme.

SMi Group caught up with Dr. Yanming Zu to talk about her role in the field and her responsibility for the generic and proprietary product development, as a registered pharmacist and her career as a Senior Principle Scientists joining Abon Pharmaceuticals back in 2009. Dr. Zu’s research and development work contributed to a number of ANDA filings and approvals, and generated several patents, research papers, review articles and presentations.

–SNAPSHOT OF INTERVIEW–

Q . What is the greatest challenge to overcome in the field at the moment?
A. Poor solubility and instability of new chemical entities are challenges in the field of lyophilisation, especially with the increasing number of the insoluble and unstable drugs."

Q. What technology has really caught your eye in the Lyophilization field in the past year?
A. Controlled nucleation is one of the most typical trends in the industry, as uncontrolled nucleation introduces significant heterogeneity affecting the product quality, while the controlled nucleation technology allows for improved uniformity, consistence and thus the product quality assurance."

– Download the full interview online – http://www.lyophilization-usa.com/PR07

At SMi’s 4th Annual Lyophilization USA 2018 Conference you will gain insight into:
• Continuous freeze-drying technologies
• Developments in bulk lyophilization technology
• How to overcome challenges in lyophilization of high concentrated solutions and high-density biologic materials
• Process optimization of lyophilization from a regulatory perspective
• Strategies to validate the lyophilization process
• Methods beyond lyophilization: Spray drying, foam drying and microwave drying
• Use of artificial intelligence in lyophilisation

The conference’s last early bird saving of $100 expires on September 28th and delegates are urged to book soon to join an unrivalled gathering of international expert speakers and industry professionals for 5+ hours of pure networking. Visit the website to download the full speaker interviews, see the agenda and keep up to date with the latest developments at http://www.lyophilization-usa.com/PR07

Follow us on: Twitter – @SMIpharm & #lyousa | LinkedIn – SMi Pharma

—- ENDS —-

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Sidhu
SMi Group
+44 (0) 207 827 6088
email us here


Source: EIN Presswire

Mary Beth McGuinn LCSW to be Featured on CUTV News Radio

RAMSEY, NEW JERSEY, UNITED STATES, August 14, 2018 /EINPresswire.com/ — Mary Beth McGuinn, LCSW is a seasoned therapist and a go-to person when working with clients going through transitions in their lives. Worry, depression and anxiety are often a consequence of not feeling confident when changes arise. Feeling disconnected from life, people often feel powerless to make the right decisions. McGuinn, LCSW uses her expertise from 20 years in a therapeutic practice to guide clients to be able to manage their lives, have less anxiety and be more confident. Mastering techniques to take things down a notch, clients leave sessions with less tension and more hope for resolving what is on their minds.

“My focus in therapy and coaching with clients is to help them be the best they can be and shift from being a victim to being a victor,” says McGuinn.

“It is not about looking at someone and saying what is wrong with this person,” says McGuinn. “I look at clients I work with and wonder, ‘What has kept them stuck in life? I explore this with my clients in therapy and help them get clear on where they are going. I am a life-long learner, always learning new information to bring to my clients from Neuroscience to Energy Psychology.”

Pairing Energy Psychology, EFT Tapping with traditional therapy and coaching, McGuinn’s integrative approach allows clients to not only clear negative thoughts but help ease tensions in your body. Her eclectic approach draws from Psychoanalysis, Cognitive Behavioral Therapy and Grief Recovery Work.

In addition to receiving Advance Standing at Adelphi University, she has done post graduate work at the New Jersey Institute for Training in Psychoanalysis and a certification from the Grief Recovery Institute. She co-authored with Jack Canfield a recent bestselling book titled the Road to Success Volume 1.

She works in Ramsey, New Jersey and can be found on the therapist directory of PsychologyToday.com.

CUTV News Radio will feature Mary Beth McGuinn in an interview with Jim Masters on July 25th at 11am EDT.

Listen to the show on BlogTalkRadio.

If you have a question for our guest, call (347) 996-3389

Lou Ceparano
CUTV News
(631) 850-3314
email us here


Source: EIN Presswire

HealthTech Healx raise $10m to accelerate drug discovery, prior to speaking at Orphan Drugs and Rare Diseases Conference

Orphan Drugs and Rare Diseases 2018

Orphan Drugs and Rare Diseases 2018

HealthTech Healx, who raised $10m to advance drug discovery & treatments for rare diseases, set to speak at 8th Annual Orphan Drugs and Rare Diseases Conference

LONDON, WATERLOO, UNITED KINGDOM, August 14, 2018 /EINPresswire.com/ — Healx, a HealthTech company based in Cambridge who are also set to speak at this year’s Orphan Drugs and Rare Diseases conference in October in London, have announced a $10m (£7.6m) Series A funding round. The company's primary focuses include using AI to develop treatments for rare diseases, cutting down the time it takes to get drugs into market, finding new uses for existing drugs and their application in combination therapies.

Patients with rare diseases cannot continue to be overlooked because of costly therapies and have the same rights to treatment as any other patient. Dr David Brown, one of the company's founders, stated “The traditional drug discovery process takes 10 to 15 years at a cost of $2 billion per new drug and with a failure rate of 95% – it’s broken, it’s slow, it’s high failure, and it’s not economic for rare diseases. Healx is showing that we can massively transform the rate of discovery of new medicines, reducing timelines and costs.”*

The orphan drugs market has seen a huge growth in interest from pharmaceutical companies and biotechs, as a growing need for effective, long-term treatment for rare disease patients becomes a priority. Companies like Healx are paving the way to success by repurposing existing drugs, meaning fewer complex trials, less expenditure, and a quicker timeline.

This year's 8th annual Orphan Drugs and Rare Diseases conference, taking place 17 – 18 October in London, will be hosting Healx's Head of Business Development Michale Bouskila-Chubb, who is set to present on "Accelerating drug discovery for rare diseases using AI: The Healx Model".

Michale will be focusing on fragile X case study: the case for AI-driven drug repurposing vs conventional drug repurposing, setting up an online tool to share data: how patient groups can accelerate data access and data quality for their rare diseases, and translating repurposed drugs to pharma: how we can build viable commercial cases for the pharmaceutical industry.

At this year’s two-day conference, delegates will be able to hear from Healx and many more industry leaders, including Sobi, MHR AstraZeneca, Genetic Alliance and more.

2018 Conference Highlights:

• Discuss the pricing and reimbursement of orphan drugs
• Understand the challenges of patient recruitment and patient-centric research
• Hear the MHRA’s perspective on benefit-risk assessment in rare diseases
• Explore the clinical development of orphan drugs for rare diseases
• Gain insight into potential synergies between regulators, non-profits and pharmaceutical companies

The conference’s last early bird saving of £200 expires on August 31st and delegates are urged to book soon to join an unrivalled gathering of international expert speakers and industry professionals for 5+ hours of pure networking. Visit the website to download the full speaker interviews, see the agenda and keep up to date with the latest developments at http://www.orphandrugs.co.uk/einpr

*uktech.news

—- END —
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Maria Mandic
SMi Group
email us here
+44 (0) 207 827 6000


Source: EIN Presswire